Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089167 · ClinicalTrials.gov registry record · Phase 2
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00089167: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00089167 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089167, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic amyloidosis.
Interventions
- DRUG dexamethasone
- DRUG melphalan
- BIOLOGICAL filgrastim
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00089167
The ClinicalTrials.gov registry entry for NCT00089167 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which dexamethasone is the first listed.
NCT00089167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00089167 about?
NCT00089167 is a clinical study titled "Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis". RATIONALE: Drugs such as melphalan, thalidomide, and dexamethasone may be effective in treating patients with primary systemic amyloidosis. PURPOSE: This phase II trial is studying how well giving melphalan together with thalidomide and dexamethasone works in treating patients with primary systemic...
What is the current status of trial NCT00089167?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-05.
What interventions are being tested in trial NCT00089167?
The interventions under investigation include: dexamethasone (DRUG), melphalan (DRUG), filgrastim (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00089167?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.